Business Wire

SEOUL-VIOSYS

20.8.2020 14:20:04 CEST | Business Wire | Press release

Share
Seoul Viosys to Promote Innovative Violeds Technology Solution Proven to Sterilize New Coronaviruses for Air Conditioning and Heating Systems

Seoul Viosys (KOSDAQ:092190), a leading compound semiconductor solution provider, announced that it promotes new Violeds technology solution, the world’s first ultraviolet LED technology proven to sterilize new coronaviruses, for air conditioning and heating systems.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200820005452/en/

Seoul Viosys will hold a campaign of pilot installation for new Violeds technology solution by August 31st , 2020 focusing on public facilities such as offices, shopping centers, and airport in the world as a part of anti-coronavirus. Inquiries and applications are available on its website (www.seoulviosys.com/en/ ) and Seoul Viosys’ partners will support additional requests after finishing the first campaign period.

Seoul Viosys provides major manufacturer of air conditioners with optimized UV LED solutions based on successful testing results of 99.9% sterilization of the new coronavirus in 30 seconds by the research group of Korea University. In June, a global air conditioner manufacturer that produces 40 million per year has adopted Violeds technology for its thirty models.

Through the results of testing by Guangzhou Institute of Microbiology in China (CGMT), Gree demonstrates that its new “Fresh Air” air conditioner with Violeds UV LED technology has the performance to sterilize 99.15% of viruses and bacteria, 98% of enteroviruses such as EV71 and H1N1, and 99% of staphylococcus albus bacteria. In addition, it has been proven to sterilize 90% of various harmful viruses in air in 2 hours when using their air conditioners.

Violeds technology has been adopted not only by the Chinese AC manufacturer Gree, but also by a leading in-duct air treatment supplier in the U.S. Seoul Viosys will provide its technology for air conditioners of a leading electronics brand.

Conventional air conditioners typically draw outside air into the AC unit, and discharge that air back into the interior after cooling and filtering, where it is continuously recirculated. This recirculation of indoor air may cause a higher risk of infection through aerosol transmission when viruses are present. The amount of dust and moisture on the cooling filter can also transmit harmful viruses. Conventional filter in air purification system can filter out general droplets or fine dust more than 0.3μm but the viruses such as new coronavirus and SARS virus itself as small as 0.1μm can pass through the HEPA filters as it is.

“As a result of successful production approval to supply Violeds products and expanding customer demand, Violeds UV LEDs have clearly been recognized as essential technology for HVAC (Heating, Ventilation, and Air Conditioning) systems. We believe that our new Violeds technology solution for disinfection of air conditioning and heating systems helps to eliminate viruses in air and protect people from COVID-19 pandemic,” said a representative of Seoul Viosys.

About Seoul Viosys

Seoul Viosys is a full-line solution provider for UV LED, VCSEL (Vertical Cavity Surface Emitting Laser), the next-generation light source for 3D sensor and laser, and a single-pixel RGB “Micro Clean Pixel” for displays. Established in 2002 as a subsidiary of Seoul Semiconductor, it captured No. 1 market share in the UV LED industry (LEDinside, 2018). Seoul Viosys has an extensive UV LED portfolio with all wavelengths ranging from 200nm to 1600nm, including ultraviolet rays (UV), visible rays, and infrared rays. The company holds more than 4,000 patents related to UV LED technology. Violeds, its flagship UV LED technology, provides a wide range of industries with optimal solutions for robust sterilization and disinfection (UV-C), skin regeneration (UV-B), water/air purification and effective cultivation for horticulture. In 2018, Seoul Viosys acquired RayCan, a leading optoelectronic specialist, to add advanced VCSEL technology, which supports smartphone facial recognition and autonomous driving, and has started mass production. In January 2020, it introduced a disruptive “Micro Clean Pixel” that has the potential to be a game-changer in the display market. To learn more, visit http://www.seoulviosys.com/en/ .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release

Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release

Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d

Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release

A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release

New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release

Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye